Hydroxyurea capsules

DRUG2 trials

Sponsors

Novartis, Hospital Universitario Dr. Jose E. Gonzalez

Conditions

AMLHyperleukocytosisRecurrent Glioblastoma Multiforme (GBM)

Phase 2

Efficacy and Safety of Imatinib Mesylate Plus Hydroxyurea (HU) in Patients With Recurrent Glioblastoma Multiforme (GBM)

TerminatedNCT00290771

NovartisRecurrent Glioblastoma Multiforme (GBM)

Start: 2006-02-28End: 2008-08-31Updated: 2011-05-16

Vinblastine for Leukoreduction in Newly Diagnosed AML and Hyperleukocytosis

Hospital Universitario Dr. Jose E. GonzalezAML, Hyperleukocytosis

Start: 2021-07-26End: 2025-12-01Target: 46Updated: 2021-10-18